Research Square·8 OctA Phase 2b randomized clinical trial of the oral p38α inhibitor neflamapimod in dementia with Lewy bodies (DLB)Preprint: trial in peopleInterventionsPaper
AAIC 2025 Abstract·23 DecEffects of neflamapimod (p38α kinase inhibitor) on clinical progression in patients with dementia with Lewy bodies (DLB) without Alzheimer’s disease (AD) Co‐PathologyTrial in peopleInterventionsPaper